Form 4 for VCEL Vericel Corp
Accepted 2023-11-22 00:00:00 ET · period of report 2023-11-20 · accession 0001140361-23-054439 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2023-11-22 | 2023-11-20 | VCEL | Hopper Jonathan Mark | Chief Medical Off | M - OptEx | $10.95 | +5,000 | 58.0K | +9% | +$54.8K |
| DT | 2023-11-22 | 2023-11-20 | VCEL | Hopper Jonathan Mark | Chief Medical Off | S - Sale+OE | $36.40 | -5,000 | 53.0K | -9% | -$182.0K |
| DT | 2023-11-22 | 2023-11-20 | VCEL | Hopper Jonathan Mark | Chief Medical Off | M - OptEx | $0.00 | +5,000 | 32.6K | +18% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-20 | M | A | 5,000 | $10.95 | 58,007 | D | — | — | (F1) These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| 2 | Common | Common Stock | 2023-11-20 | S | D | 5,000 | $36.40 | 53,007 | D | — | — | (F2) The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 17, 2023. (F1) These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| 3 | Derivative | Stock Option (Right to Buy) | 2023-11-20 | M | A | 5,000 | $0.00 | 32,604 | D | $10.95 · — to 2028-08-20 | 5,000 Common Stock | (F3) These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company. |